Application of DCE-MRI radiomics signature analysis in differentiating molecular subtypes of luminal and non-luminal breast cancer
BackgroundThe goal of this study was to develop and validate a radiomics signature based on dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) preoperatively differentiating luminal and non-luminal molecular subtypes in patients with invasive breast cancer.MethodsOne hundred and thirty-f...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-04-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2023.1140514/full |
| _version_ | 1797840040490958848 |
|---|---|
| author | Ting Huang Bing Fan Yingying Qiu Rui Zhang Xiaolian Wang Chaoxiong Wang Huashan Lin Ting Yan Wentao Dong |
| author_facet | Ting Huang Bing Fan Yingying Qiu Rui Zhang Xiaolian Wang Chaoxiong Wang Huashan Lin Ting Yan Wentao Dong |
| author_sort | Ting Huang |
| collection | DOAJ |
| description | BackgroundThe goal of this study was to develop and validate a radiomics signature based on dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) preoperatively differentiating luminal and non-luminal molecular subtypes in patients with invasive breast cancer.MethodsOne hundred and thirty-five invasive breast cancer patients with luminal (n = 78) and non-luminal (n = 57) molecular subtypes were divided into training set (n = 95) and testing set (n = 40) in a 7:3 ratio. Demographics and MRI radiological features were used to construct clinical risk factors. Radiomics signature was constructed by extracting radiomics features from the second phase of DCE-MRI images and radiomics score (rad-score) was calculated. Finally, the prediction performance was evaluated in terms of calibration, discrimination, and clinical usefulness.ResultsMultivariate logistic regression analysis showed that no clinical risk factors were independent predictors of luminal and non-luminal molecular subtypes in invasive breast cancer patients. Meanwhile, the radiomics signature showed good discrimination in the training set (AUC, 0.86; 95% CI, 0.78–0.93) and the testing set (AUC, 0.80; 95% CI, 0.65–0.95).ConclusionThe DCE-MRI radiomics signature is a promising tool to discrimination luminal and non-luminal molecular subtypes in invasive breast cancer patients preoperatively and noninvasively. |
| first_indexed | 2024-04-09T16:08:00Z |
| format | Article |
| id | doaj.art-d77fb669bfd14fa5972e3115e2e556b3 |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-04-09T16:08:00Z |
| publishDate | 2023-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-d77fb669bfd14fa5972e3115e2e556b32023-04-25T04:36:45ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2023-04-011010.3389/fmed.2023.11405141140514Application of DCE-MRI radiomics signature analysis in differentiating molecular subtypes of luminal and non-luminal breast cancerTing Huang0Bing Fan1Yingying Qiu2Rui Zhang3Xiaolian Wang4Chaoxiong Wang5Huashan Lin6Ting Yan7Wentao Dong8Department of Radiology, Jiangxi Provincial People’s Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, ChinaDepartment of Radiology, Jiangxi Provincial People’s Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, ChinaDepartment of Radiology, Jiangxi Provincial People’s Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, ChinaDepartment of Radiology, Jiangxi Provincial People’s Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, ChinaDepartment of Radiology, Jiangxi Provincial People’s Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, ChinaDepartment of Radiology, Jiangxi Provincial People’s Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, ChinaDepartment of Pharmaceutical Diagnosis, GE Healthcare, Changsha, ChinaDepartment of Radiology, Jiangxi Provincial People’s Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, ChinaDepartment of Radiology, Jiangxi Provincial People’s Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, ChinaBackgroundThe goal of this study was to develop and validate a radiomics signature based on dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) preoperatively differentiating luminal and non-luminal molecular subtypes in patients with invasive breast cancer.MethodsOne hundred and thirty-five invasive breast cancer patients with luminal (n = 78) and non-luminal (n = 57) molecular subtypes were divided into training set (n = 95) and testing set (n = 40) in a 7:3 ratio. Demographics and MRI radiological features were used to construct clinical risk factors. Radiomics signature was constructed by extracting radiomics features from the second phase of DCE-MRI images and radiomics score (rad-score) was calculated. Finally, the prediction performance was evaluated in terms of calibration, discrimination, and clinical usefulness.ResultsMultivariate logistic regression analysis showed that no clinical risk factors were independent predictors of luminal and non-luminal molecular subtypes in invasive breast cancer patients. Meanwhile, the radiomics signature showed good discrimination in the training set (AUC, 0.86; 95% CI, 0.78–0.93) and the testing set (AUC, 0.80; 95% CI, 0.65–0.95).ConclusionThe DCE-MRI radiomics signature is a promising tool to discrimination luminal and non-luminal molecular subtypes in invasive breast cancer patients preoperatively and noninvasively.https://www.frontiersin.org/articles/10.3389/fmed.2023.1140514/fullradiomics signaturemolecular subtypesluminalbreast cancermagnetic resonance imaging |
| spellingShingle | Ting Huang Bing Fan Yingying Qiu Rui Zhang Xiaolian Wang Chaoxiong Wang Huashan Lin Ting Yan Wentao Dong Application of DCE-MRI radiomics signature analysis in differentiating molecular subtypes of luminal and non-luminal breast cancer Frontiers in Medicine radiomics signature molecular subtypes luminal breast cancer magnetic resonance imaging |
| title | Application of DCE-MRI radiomics signature analysis in differentiating molecular subtypes of luminal and non-luminal breast cancer |
| title_full | Application of DCE-MRI radiomics signature analysis in differentiating molecular subtypes of luminal and non-luminal breast cancer |
| title_fullStr | Application of DCE-MRI radiomics signature analysis in differentiating molecular subtypes of luminal and non-luminal breast cancer |
| title_full_unstemmed | Application of DCE-MRI radiomics signature analysis in differentiating molecular subtypes of luminal and non-luminal breast cancer |
| title_short | Application of DCE-MRI radiomics signature analysis in differentiating molecular subtypes of luminal and non-luminal breast cancer |
| title_sort | application of dce mri radiomics signature analysis in differentiating molecular subtypes of luminal and non luminal breast cancer |
| topic | radiomics signature molecular subtypes luminal breast cancer magnetic resonance imaging |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2023.1140514/full |
| work_keys_str_mv | AT tinghuang applicationofdcemriradiomicssignatureanalysisindifferentiatingmolecularsubtypesofluminalandnonluminalbreastcancer AT bingfan applicationofdcemriradiomicssignatureanalysisindifferentiatingmolecularsubtypesofluminalandnonluminalbreastcancer AT yingyingqiu applicationofdcemriradiomicssignatureanalysisindifferentiatingmolecularsubtypesofluminalandnonluminalbreastcancer AT ruizhang applicationofdcemriradiomicssignatureanalysisindifferentiatingmolecularsubtypesofluminalandnonluminalbreastcancer AT xiaolianwang applicationofdcemriradiomicssignatureanalysisindifferentiatingmolecularsubtypesofluminalandnonluminalbreastcancer AT chaoxiongwang applicationofdcemriradiomicssignatureanalysisindifferentiatingmolecularsubtypesofluminalandnonluminalbreastcancer AT huashanlin applicationofdcemriradiomicssignatureanalysisindifferentiatingmolecularsubtypesofluminalandnonluminalbreastcancer AT tingyan applicationofdcemriradiomicssignatureanalysisindifferentiatingmolecularsubtypesofluminalandnonluminalbreastcancer AT wentaodong applicationofdcemriradiomicssignatureanalysisindifferentiatingmolecularsubtypesofluminalandnonluminalbreastcancer |